Back to top

Names Under Consideration

Back to top

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more. 

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

September 2016

biropepimut-s: antineoplastic

diroximel fumarate: treatment of multiple sclerosis

efizonerimod: antineoplastic

ingenol disoxate: treatment of actinic keratosis

omirsen: treatment of hematologic malignancies

prexigbersen: treatment of hematologic malignancies, inflammation and autoimmune disease

relatlumab: treatment of cancer

August 2016

gosuranezumab: treatment of progressive supranuclear palsy (PSP)

otamilast: treatment of atopic dermatitis, topical agent

rosuranezumab: treatment of progressive supranuclear palsy (PSP)

July 2016

bravilizumab: treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)

crenigacestat: antineoplastic

cofetuzumab: treatment of oncology

emplumab: treatment of cancer

etsantuzumab: treatment of oncology

evispectinib: treatment of cancer

hafnium oxide: radiation sensitizer

metamide methyl fumarate: treatment of multiple sclerosis, psoriasis

mirikizumab: treatment of autoimmune diseases

otanvimilast: treatment of atopic dermatitis, topical agent

pegilodecakin: treatment of advanced solid tumors

ralaniten: treatment of prostate cancer

rasdelumab nesotigen: treatment of malignancies expressing NY-ESO-1

setocabtagene pirtaretroleucel: treatment of leukemia

talditermant alfa: treatment of duchenne muscular dystrophy, spinal muscular atrophy, ALS

tibulizumab: treatment of autoimmune disorders

tracaronase: treatment of spinal cord injury

vesbictinib: antineoplastic

Email this page